SLGL Sol-Gel Technologies Ltd.: Company Book Value

Sol-Gel Technologies (SLGL) revenues are based on the sale of patented treatments for rosacea and acne, including Twyneo and Epsolay. The business is currently burning through existing capital by directing resources into R&D, which is partially offset by licensing fees. This market price chart with the 0.05 indicator reflects the asset's dynamics. Risks are minimized through the implementation of proprietary encapsulation and a combination of direct sales and partner royalties.

Book value capitalization reflects the real value of Sol-Gel Technologies (SLGL) net assets, capturing the difference between total assets and aggregate liabilities to assess fundamental capital stability. Analyzing the company's book capitalization chart, an investor can see the impact of geopolitical instability and supply chain disruptions on the cost of material resources required for the production of dermatological drugs amid limited international technology exchange.